CA2923672A1 - Diagnostic de sous-groupes lies a idh1 et traitement du cancer - Google Patents

Diagnostic de sous-groupes lies a idh1 et traitement du cancer Download PDF

Info

Publication number
CA2923672A1
CA2923672A1 CA2923672A CA2923672A CA2923672A1 CA 2923672 A1 CA2923672 A1 CA 2923672A1 CA 2923672 A CA2923672 A CA 2923672A CA 2923672 A CA2923672 A CA 2923672A CA 2923672 A1 CA2923672 A1 CA 2923672A1
Authority
CA
Canada
Prior art keywords
regulation
akt
subject
cell
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2923672A
Other languages
English (en)
Inventor
Anna Joy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dignity Health
Original Assignee
Dignity Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dignity Health filed Critical Dignity Health
Publication of CA2923672A1 publication Critical patent/CA2923672A1/fr
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
    • C12Q2565/50—Detection characterised by immobilisation to a surface
    • C12Q2565/501—Detection characterised by immobilisation to a surface being an array of oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Cette invention concerne la classification, le diagnostic et le traitement de cancers. Dans un mode de réalisation, cette invention concerne des méthodes et des kits permettant de classifier les cancers en divers sous-types sur la base des profils d'expression des composants de la voie AKT. Dans un autre mode de réalisation, cette invention concerne des méthodes et des kits permettant de diagnostiquer des sous-types de cancers par évaluation des profils d'expression des composants de la voie AKT. Dans un autre mode de réalisation encore, cette invention concerne des méthodes et des kits permettant de traiter un sous-type de cancer par administration d'un agent d'alkylation ou d'un inhibiteur de PI3K/AKT/mTOR à un patient. Les cancers se prêtant aux divers modes de réalisation selon l'invention comprennent, entre autres, les tumeurs du cerveau, les gliomes et GBM.
CA2923672A 2013-11-22 2014-11-24 Diagnostic de sous-groupes lies a idh1 et traitement du cancer Pending CA2923672A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361907987P 2013-11-22 2013-11-22
US61/907,987 2013-11-22
PCT/US2014/067168 WO2015077725A1 (fr) 2013-11-22 2014-11-24 Diagnostic de sous-groupes liés à idh1 et traitement du cancer

Publications (1)

Publication Number Publication Date
CA2923672A1 true CA2923672A1 (fr) 2015-02-28

Family

ID=53180271

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2923672A Pending CA2923672A1 (fr) 2013-11-22 2014-11-24 Diagnostic de sous-groupes lies a idh1 et traitement du cancer

Country Status (2)

Country Link
CA (1) CA2923672A1 (fr)
WO (1) WO2015077725A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10731221B2 (en) 2009-12-11 2020-08-04 Dignity Health Diagnosing IDH1 related subgroups and treatment of cancer

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210355545A1 (en) * 2018-10-15 2021-11-18 The Johns Hopkins University Methods and materials for assessing and treating cancer
EP4013866A4 (fr) 2019-08-16 2023-08-30 Tempus Labs, Inc. Systèmes et procédés de détection d'un dérèglement de la voie cellulaire dans des échantillons de cancer
WO2021119641A1 (fr) * 2019-12-12 2021-06-17 Tempus Labs, Inc. Preuve du monde réel de tests de diagnostic et de schémas de traitement chez des patientes américaines atteintes d'un cancer du sein
CN114752677B (zh) * 2022-06-13 2022-09-02 北京思诺普斯生物科技有限公司 一种快速检测idh1突变的引物组、试剂盒及扩增方法和应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2633593A1 (fr) * 2005-12-16 2007-10-04 Genentech, Inc. Methode de diagnostic, de pronostic et de traitement du gliome

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10731221B2 (en) 2009-12-11 2020-08-04 Dignity Health Diagnosing IDH1 related subgroups and treatment of cancer

Also Published As

Publication number Publication date
WO2015077725A1 (fr) 2015-05-28

Similar Documents

Publication Publication Date Title
US20200340066A1 (en) Diagnosing idh1 related subgroups and treatment of cancer
EP3458604B1 (fr) Procédé de détermination de la sensibilité à un inhibiteur cdk4/6
Jovčevska Genetic secrets of long-term glioblastoma survivors
US20160010159A1 (en) Gene signature to predict homologous recombination (hr) deficient cancer
CA2923672A1 (fr) Diagnostic de sous-groupes lies a idh1 et traitement du cancer
TW201717951A (zh) 以法呢基轉移酶（farnesyltransferase）抑制劑治療癌症病患之方法
CA2867375A1 (fr) Methodes et compositions pour le diagnostic, le pronostic et le traitement de la leucemie myeloide aigue
WO2015100257A1 (fr) Procédés et dosages pour la détermination d'une fonction de voie brca1 réduite dans une cellule cancéreuse
US11352671B2 (en) Predicting therapeutic response in Parkinson's disease
EP3502269B1 (fr) Détection du cancer du cerveau
US20180011102A1 (en) The protein kinase activity of phosphoglycerate kinase 1 as a target for cancer treatment and diagnosis
WO2017120285A1 (fr) Procédés d'utilisation de micro-arn provenant de liquides organiques pour le diagnostic et la surveillance de troubles neurodéveloppementaux
US9845504B2 (en) Method for treating rheumatoid arthritis with agents that recognize the B-lymphocyte CD20 membrane receptor
US20230383357A1 (en) Subject-specific treatments for venetoclax-resistant acute myeloid leukemia
US20230279491A1 (en) Treatments for a sub-population of inflammatory bowel disease patients
CN108715893B (zh) 一组与放疗引起的放射性脑损伤相关的snp标志物及其应用
US20240034799A1 (en) Methods and systems of stratifying inflammatory disease patients
Li et al. Identification of hub genes associated with outcome of clear cell renal cell carcinoma
Guo et al. Identification of key genes and molecular mechanisms of chronic urticaria based on bioinformatics
US20150017210A1 (en) Gene Signature Predicts Adenocarcinoma Prognosis and Therapeutic Response
WO2021050937A1 (fr) Procédés pour le traitement de cancers déficitaires d'arid1a
US20190271689A1 (en) Method of predicting progression of idiopathic pulmonary fibrosis and monitoring of therapeutic efficacy
Kazerooni et al. EPCO-25. MULTI-OMICS DISEASE STRATIFICATION IN PATIENTS WITH IDH-WILDTYPE GLIOBLASTOMA: SYNERGISTIC VALUE OF CLINICAL MEASURES, CONVENTIONAL AND DEEP RADIOMICS, AND GENOMICS FOR PREDICTION OF OVERALL SURVIVAL
Shixuan et al. Pharmaceutical Repurposing Strategies for Metabolic Disorders: Insights from Mendelian Randomization Studies
Du et al. Machine learning algorithms integrate bulk and single-cell RNA data to unveil oxidative stress following intracerebral hemorrhage

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191122

EEER Examination request

Effective date: 20191122

EEER Examination request

Effective date: 20191122

EEER Examination request

Effective date: 20191122

EEER Examination request

Effective date: 20191122

EEER Examination request

Effective date: 20191122